Peer-reviewed research publishing this month is uncovering new data about the importance of what happens with a woman's body after ovulation when trying to conceive
BOULDER, Colo., Sept. 29, 2022 /PRNewswire-PRWeb/ -- Proov, makers of the first and only FDA-cleared PdG-test and the first full cycle tracking kit, is announcing first of its kind findings that should help inform the medical community and American women surrounding the role of PdG.
The research just published this month in the Journal of Obstetrics & Gynecology Research: https://www.fortunejournals.com/abstract/the-predictive-value-of-urinary-progesterone-metabolite-pdg-testing-in-pregnancy-outcomes-3533.html. Proov's study has shown that Positive PdG cycles are associated with increased pregnancy rates and lower odds of a first-trimester pregnancy loss. This demonstrates an increased need for consideration for luteal phase support with progesterone or ovulation induction in women with negative PdG cycles and that this can be of benefit. Furthermore, the use of LH and PdG testing prior to conception can be used as a screening tool to potentially identify women who are at risk of subfertility and at a higher risk of first-trimester pregnancy loss related to low progesterone.
These critical findings are now being released at a time when we are paying closer attention to potential inaccuracies with the traditional Ovulation tests that have been developed and marketed for the last several decades. Proov has always focused its time, research, and diagnostic development on what happens after ovulation. Much of this is due to founder and inventor, Amy Beckley's, own confusing experiences with these at-home tests.
"Mounting evidence is showing us that LH doesn't have anything to do with ovulation, it can surge at any time and doesn't necessarily mean that you're ovulating," said Amy Beckley, Proov's founder and CEO. "Yet, despite this, women worldwide are still turning to this method of testing when trying to get pregnant. It's important to understand that LH shouldn't be the only thing we're following, after all this test was developed in 1989 - we need to start advancing our understanding for a more comprehensive picture of a woman's hormonal health."
Recently as well, a new lawsuit has been filed against some of the top ovulation test kit manufacturers due to an overwhelming amount of unreliable results for consumers. Proov is aiming to shine a light on this issue and help educate the community not only about this concerning trend, but new considerations to take into account with the often overlooked PdG hormone as a way to confirm successful ovulation has indeed occurred.
For more questions about the release of Proov's peer-reviewed research please contact Kristen Mondshein.
About MFB Fertility, Inc.
MFB Fertility, Inc. developed Proov®, an at-home PdG test that measures the presence of progesterone metabolite PdG in urine to help a woman confirm that she has ovulated successfully. Originally co-founded in Boulder, Colo. by two women who both struggled to conceive, MFB Fertility was created to empower women to know more about their menstrual cycles, ovulation health, and PdG levels. Don't just predict ovulation, Proov it! For more information, please visit https://proovtest.com/.
Media Contact
Kristen Mondshein
kristen@kmmcommunications.com
Media Contact
Kristen Mondshein, KMM Communications, 1 3058773293, kristen@kmmcommunications.com
SOURCE Proov
Share this article